Treatment and prophylaxis of sepsis and septic shock
A method and composition for the prophylaxis or treatment of humans or animals for septic shock and sepsis using a mixture of sophorolipids.
1. A method for producing sophorolipids for treatment of sepsis and septic shock in a human or animal comprising the steps of:
a. synthesizing the sophorolipids by fermentation of Candida bombicola in a fermentation media to form a natural mixture of lactonic sophorolipids and non-lactonic sophorolipids;
b. utilizing the natural mixture for treatment of sepsis and septic shock in a human or animal;
c. separating the lactonic sophorolipids from the natural mixture to form a lactonic fraction and mixing all remaining fractions to form a non-lactonic fraction;
d. utilizing the lactonic fraction for treatment of sepsis and septic shock in a human or animal; and
e. utilizing the non-lactonic fraction for treatment of sepsis and septic shock in a human or animal.
2. The method as claimed in claim 1 , wherein one of the sophorolipids produced comprises 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate.
3. The method as claimed in claim 1 , wherein one of the sophorolipids produced is selected from the group consisting of 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate-6′,6″-diacetate, Hexyl 17-L[(2′-O-β-D glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate,and Ethyl 17-L[(2′-O-β-D glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate.
4. The method as claimed in claim 1 , wherein the mixture is administered by a method selected from the group consisting of intraperitoneal administration, intraarterial administration, and intravenous administration.
5. The method as claimed in claim 1 , wherein the mixture is administered in a dose of between about 2 mg of the mixture per kilogram of the human or animal and about 30 mg of the mixture per kilogram of the human or animal.
6. A method for producing sophorolipids for treatment of sepsis and septic shock in a human or animal comprising the steps of:
a. synthesizing the sophorolipid by fermentation of Candida bombicola in a fermentation media to form a natural mixture of lactonic sophorolipids and non-lactonic sophorolipids; and
b. utilizing the natural mixture for treatment of sepsis and septic shock in a human or animal.
7. The method as claimed in claim 6 , wherein one of the sophorolipids produced comprises 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate.
8. The method as claimed in claim 6 , wherein one of the sophorolipids produced is selected from the group consisting of 17-L-[(2′-O-β-D-glucopyranosyl-β-D-gucopyranosyl)-oxyl]-cis-9-octadecenoate-6′,6″-diacetate, Hexyl 17-L[(2′-O-β-D glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate,and Ethyl 17-L[(2′-O-β-D glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate.
9. The method as claimed in claim 6 , wherein the mixture is administered by a method selected from the group consisting of intraperitoneal administration, intraarterial administration, and intravenous administration.
10. The method as claimed in claim 6 , wherein the mixture is administered in a dose of between about 2 mg of the mixture per kilogram of the human or animal and about 30 mg of the mixture per kilogram of the human or animal.
11. A method for producing sophorolipids for treatment of sepsis and septic shock in a human or animal comprising the steps of:
a. synthesizing the sophorolipid by fermentation of Candida bombicola in a fermentation media to form a natural mixture of lactonic sophorolipids and non-lactonic sophorolipids;
b. separating the lactonic sophorolipids from the natural mixture to form a lactonic fraction and mixing all remaining fractions to form a non-lactonic fraction; and
c. utilizing the lactonic fraction for treatment of sepsis and septic shock in a human or animal.
12. The method as claimed in claim 11 , wherein one of the sophorolipids produced comprises 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate.
13. The method as claimed in claim 11 , wherein the mixture is administered by a method selected from the group consisting of intraperitoneal administration, intraarterial administration, and intravenous administration.
14. The method as claimed in claim 11 , wherein the mixture is administered in a dose of between about 2 mg of the mixture per kilogram of the human or animal and about 30 mg of the mixture per kilogram of the human or animal.
15. A method for producing sophorolipids for treatment of sepsis and septic shock in a human or animal comprising the steps of:
a. synthesizing the sophorolipid by fermentation of Candida bombicola in a fermentation media to form a natural mixture of lactonic sophorolipids and non-lactonic sophorolipids;
b. separating the lactonic sophorolipids from the natural mixture to form a lactonic fraction and mixing all remaining fractions to form a non-lactonic fraction; and
c. utilizing the non-lactonic fraction for treatment of sepsis and septic shock in a human or animal.
16. The method as claimed in claim 15 , wherein one of the sophorolipids produced comprises 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate.
17. The method as claimed in claim 15 , wherein one of the sophorolipids produced is selected from the group consisting of 17-L-[(2′-O-β-D-glucopyranosyl-β-D-gucopyranosyl)-oxy]-cis-9-octadecenoate-6′,6″-diacetate, Hexyl 17-L[(2′-O-β-D glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate,and Ethyl 17-L[(2′-O-β-D glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate.
18. The method as claimed in claim 15 , wherein the mixture is administered by a method selected from the group consisting of intraperitoneal administration, intraarterial administration, and intravenous administration.
19. The method as claimed in claim 15 , wherein the mixture is administered in a dose of between about 2 mg of the mixture per kilogram of the human or animal and about 30 mg of the mixture per kilogram of the human or animal.